WO2006127899A3 - (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use - Google Patents

(r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use Download PDF

Info

Publication number
WO2006127899A3
WO2006127899A3 PCT/US2006/020233 US2006020233W WO2006127899A3 WO 2006127899 A3 WO2006127899 A3 WO 2006127899A3 US 2006020233 W US2006020233 W US 2006020233W WO 2006127899 A3 WO2006127899 A3 WO 2006127899A3
Authority
WO
WIPO (PCT)
Prior art keywords
synthesis
methylnaltrexone
processes
pharmaceutical use
mntx
Prior art date
Application number
PCT/US2006/020233
Other languages
French (fr)
Other versions
WO2006127899A2 (en
Inventor
Harold D Doshan
Julio Perez
Original Assignee
Progenics Pharm Inc
Harold D Doshan
Julio Perez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36997886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006127899(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK06771163.0T priority Critical patent/DK1913001T3/en
Priority to SI200631663T priority patent/SI1913001T1/en
Priority to CA2609662A priority patent/CA2609662C/en
Priority to CN200680022957XA priority patent/CN101208344B/en
Priority to BRPI0611162-9A priority patent/BRPI0611162A2/en
Application filed by Progenics Pharm Inc, Harold D Doshan, Julio Perez filed Critical Progenics Pharm Inc
Priority to JP2008513707A priority patent/JP5213704B2/en
Priority to EP06771163.0A priority patent/EP1913001B1/en
Priority to AU2006249911A priority patent/AU2006249911C1/en
Priority to MX2007014880A priority patent/MX2007014880A/en
Priority to PL06771163T priority patent/PL1913001T3/en
Priority to ES06771163T priority patent/ES2429160T3/en
Publication of WO2006127899A2 publication Critical patent/WO2006127899A2/en
Publication of WO2006127899A3 publication Critical patent/WO2006127899A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/141111—Diverse hetero atoms in same or different rings [e.g., alkaloids, opiates, etc.]

Abstract

This invention relates to stereoselective synthesis of R-MNTX and intermediates thereof, pharmaceutical preparations comprising R-MNTX or intermediates thereof and methods for their use.
PCT/US2006/020233 2005-05-25 2006-05-25 (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use WO2006127899A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ES06771163T ES2429160T3 (en) 2005-05-25 2006-05-25 (R) -N-methylnaltrexone, processes for its synthesis and pharmaceutical use
EP06771163.0A EP1913001B1 (en) 2005-05-25 2006-05-25 (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
CA2609662A CA2609662C (en) 2005-05-25 2006-05-25 (r)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
CN200680022957XA CN101208344B (en) 2005-05-25 2006-05-25 (R)-N-methylnaltrexone, processes for its synthesis and its pharmaceutical use
BRPI0611162-9A BRPI0611162A2 (en) 2005-05-25 2006-05-25 (r) -n-methylnaltrexone, process for its synthesis and pharmaceutical use
DK06771163.0T DK1913001T3 (en) 2005-05-25 2006-05-25 (R) -N-METHYLNALTREXON, METHODS OF SYNTHESIS AND PHARMACEUTICAL APPLICATION
JP2008513707A JP5213704B2 (en) 2005-05-25 2006-05-25 (R) -N-methylnaltrexone, synthesis method thereof and pharmaceutical use thereof
SI200631663T SI1913001T1 (en) 2005-05-25 2006-05-25 (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
AU2006249911A AU2006249911C1 (en) 2005-05-25 2006-05-25 (R)-N-methylnaltrexone, processes for its synthesis and its pharmaceutical use
MX2007014880A MX2007014880A (en) 2005-05-25 2006-05-25 (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use.
PL06771163T PL1913001T3 (en) 2005-05-25 2006-05-25 (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68461605P 2005-05-25 2005-05-25
US60/684,616 2005-05-25

Publications (2)

Publication Number Publication Date
WO2006127899A2 WO2006127899A2 (en) 2006-11-30
WO2006127899A3 true WO2006127899A3 (en) 2007-02-08

Family

ID=36997886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/020233 WO2006127899A2 (en) 2005-05-25 2006-05-25 (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use

Country Status (20)

Country Link
US (6) US7674904B2 (en)
EP (3) EP3219717A1 (en)
JP (4) JP5213704B2 (en)
CN (2) CN102721756A (en)
AR (1) AR057035A1 (en)
AU (1) AU2006249911C1 (en)
BR (1) BRPI0611162A2 (en)
CA (1) CA2609662C (en)
DK (1) DK1913001T3 (en)
ES (1) ES2429160T3 (en)
GT (1) GT200600226A (en)
HK (1) HK1244267A1 (en)
HN (1) HN2006019068A (en)
MX (1) MX2007014880A (en)
MY (1) MY151036A (en)
PL (1) PL1913001T3 (en)
PT (1) PT1913001E (en)
SI (1) SI1913001T1 (en)
TW (1) TWI383984B (en)
WO (1) WO2006127899A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9518062B2 (en) 2009-07-16 2016-12-13 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
US9526723B2 (en) 2008-03-21 2016-12-27 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
DK2368553T3 (en) * 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
CN1767855A (en) * 2003-04-08 2006-05-03 普罗热尼奇制药公司 Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
US20050004155A1 (en) * 2003-04-08 2005-01-06 Boyd Thomas A. Use of methylnaltrexone to treat irritable bowel syndrome
US20060205753A1 (en) * 2005-01-20 2006-09-14 Israel Robert J Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
MX2007010833A (en) 2005-03-07 2009-02-17 Univ Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration.
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US7767388B2 (en) * 2005-05-16 2010-08-03 Nutech Ventures Method for monitoring the stereoselectivity and relative rate of organic chemical reactions
AR057325A1 (en) 2005-05-25 2007-11-28 Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057035A1 (en) * 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
WO2007140272A2 (en) 2006-05-26 2007-12-06 Pharmacofore, Inc. Controlled release of phenolic opioids
TW200815451A (en) * 2006-08-04 2008-04-01 Wyeth Corp 6-carboxy-normorphinan derivatives, synthesis and uses thereof
TWI489984B (en) 2006-08-04 2015-07-01 Wyeth Corp Formulations for parenteral delivery of compounds and uses thereof
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP2099764B1 (en) 2006-09-20 2011-07-27 Mallinckrodt Inc. Preparation of substituted morphinan-6-ones and salts and intermediates thereof
EP2101773A2 (en) * 2006-11-22 2009-09-23 Progenics Pharmaceuticals, Inc. (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
BRPI0719587A2 (en) * 2006-11-22 2013-12-17 Progenics Pharm Inc (S) - 7,8-SATURATED-4,5-EPOXY-MORFINAN ANALOG STEREO ISOMERS
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
AU2008223328B2 (en) * 2007-03-06 2012-10-11 SpecGx LLC Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
CA2682125C (en) * 2007-03-29 2015-06-16 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
MX351611B (en) 2007-03-29 2017-10-20 Wyeth Llc Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof.
MX2009010474A (en) 2007-03-29 2009-10-19 Daiichi Sankyo Co Ltd Pharmaceutical composition.
AU2014201056B2 (en) * 2007-03-29 2016-06-09 Progenics Pharmaceuticals, Inc. Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof
DK2139890T3 (en) * 2007-03-29 2014-08-25 Wyeth Llc PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND APPLICATIONS THEREOF
WO2008138383A1 (en) * 2007-05-16 2008-11-20 Cilag Ag Method for the production of n-methyl naltrexone bromide
WO2009009292A2 (en) * 2007-07-11 2009-01-15 Mallinckrodt Inc. Crystalline forms of naltrexone methobromide
US8159331B2 (en) * 2007-07-17 2012-04-17 Psion Teklogix Inc. Method and system for radiated power control for short range RFID tag reading
CN101959892B (en) 2008-02-06 2014-01-08 普罗热尼奇制药公司 Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
WO2009099410A1 (en) * 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r)-8-keto-methylnaltrexone
NZ589496A (en) 2008-05-27 2013-02-22 Mallinckrodt Llc Processes and compounds for the preparation of normorphinans
CN101607963B (en) 2008-06-20 2013-04-03 重庆医药工业研究院有限责任公司 Morphinan derivatives and preparation method thereof
US9458109B2 (en) 2008-09-03 2016-10-04 Mallinckrodt Llc Substituted berbines and processes for their synthesis
CN101685084B (en) * 2008-09-22 2013-09-25 重庆医药工业研究院有限责任公司 Method for detecting methylnaltrexone bromide and impurity thereof by chromatography
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN101732243B (en) * 2008-11-26 2012-12-05 重庆医药工业研究院有限责任公司 Stable methyl naltrexone injection and preparation method thereof
CA2747427C (en) 2008-12-17 2015-10-13 Daiichi Sankyo Company, Limited Method for producing diamine derivative
JPWO2010082531A1 (en) 2009-01-13 2012-07-05 第一三共株式会社 Activated blood coagulation factor inhibitor
JP5784507B2 (en) * 2009-02-23 2015-09-24 マリンクロッド エルエルシー (+)-Morphinanium quaternary salt and method for producing the same
WO2010096791A1 (en) 2009-02-23 2010-08-26 Mallinckrodt Inc. (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
CN102325777B (en) 2009-02-23 2015-08-12 马林克罗特公司 (+)-morphinan * N-oxide compound and preparation method thereof
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
WO2010104078A1 (en) 2009-03-10 2010-09-16 第一三共株式会社 Process for producing diamine derivative
CN102348680B (en) 2009-03-13 2014-11-05 第一三共株式会社 Method for producing optically active diamine derivative
NZ595591A (en) 2009-04-24 2013-11-29 Univ Brock Processes for the preparation of morphinane and morphinone compounds
WO2010131663A1 (en) * 2009-05-15 2010-11-18 第一三共株式会社 Oxamide derivative
RU2012101649A (en) 2009-06-18 2013-07-27 Дайити Санкио Компани, Лимитед PHARMACEUTICAL COMPOSITION Possessing Enhanced Solubility
CN101845047B (en) * 2009-12-31 2011-12-07 南京臣功制药有限公司 Method for preparing methylnaltrexone bromide
WO2011112816A1 (en) 2010-03-11 2011-09-15 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
ES2601884T3 (en) 2010-03-19 2017-02-16 Daiichi Sankyo Company, Limited Procedure to improve the dissolution capacity of an anticoagulant
CA2793413C (en) 2010-03-19 2015-11-24 Daiichi Sankyo Company, Limited Crystal form of edoxaban tosylate monohydrate and method of producing same
HUE031961T2 (en) 2010-07-02 2017-09-28 Daiichi Sankyo Co Ltd Process for preparation of optically active diamine derivative salt
CN102336760B (en) * 2010-07-23 2016-04-06 重庆医药工业研究院有限责任公司 The preparation method of bromized morphinan quaternary ammonium salt
CN102565203B (en) * 2010-12-07 2015-01-07 重庆医药工业研究院有限责任公司 Method for separating and determining methyhaaltrexone bromide and impurities thereof with liquid chromatography
CN102558189B (en) * 2010-12-17 2014-09-03 北大方正集团有限公司 Refining method of methyhaaltrexone bromide
CN102565205B (en) * 2010-12-17 2014-04-09 北大方正集团有限公司 Quality detection method of methyhaaltrexone bromide
CN102558190B (en) * 2010-12-30 2014-10-22 天津康鸿医药科技发展有限公司 (R)-N-brooethyl naltrexone crystal form compound and preparation method, combination and application thereof
WO2013022059A1 (en) 2011-08-10 2013-02-14 第一三共株式会社 Pharmaceutical composition containing diamine derivative
RU2014112493A (en) 2011-09-08 2015-10-20 МАЛЛИНКРОДТ Эл-Эл-Си PRODUCTION OF ALKALOIDS WITHOUT ISOLATION OF INTERMEDIATE PRODUCTS
CN103172640A (en) * 2011-12-22 2013-06-26 天津康鸿医药科技发展有限公司 Preparation method of (R)-N-bromine-methyl naltrexone and naltrexone derivatives
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
CN104224734A (en) * 2014-08-15 2014-12-24 南京优科生物医药有限公司 Dezocine freeze-dried powder injection and preparation method thereof
CA3002137A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
CN105985348B (en) * 2015-02-12 2019-02-01 正大天晴药业集团股份有限公司 A kind of preparation method of methylnaltrexone bromide
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
US20160256453A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation induced by high opiate dosage regimen
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation
CN107782820A (en) * 2016-08-31 2018-03-09 江苏正大丰海制药有限公司 The assay method of genetoxic impurity ethyl p-toluenesulfonate in a kind of brufen
WO2020023486A1 (en) 2018-07-23 2020-01-30 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
CA3137488C (en) 2019-05-07 2023-10-31 Bausch Health Ireland Limited Liquid oral dosage formulations of methylnaltrexone
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
CN111487336B (en) * 2020-04-13 2022-08-19 司法鉴定科学研究院 Method for analyzing 37 fentanyl novel psychoactive substances in hair
CA3177250A1 (en) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
CN114152699A (en) * 2021-12-22 2022-03-08 北京金城泰尔制药有限公司 Method for determining content of glyceryl monostearate and glyceryl distearate in promestrene cream

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
WO2004043964A2 (en) * 2002-11-08 2004-05-27 Mallinckrodt Inc. Process for the preparation of quaternary n-alkyl morphinan alkaloid salts

Family Cites Families (254)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1420015B1 (en) 1959-10-16 1971-08-26 Boehringer Sohn Ingelheim 2'-Hydroxy-5,9-dimethyl-6,7-benzomorphane
GB1202148A (en) 1968-03-06 1970-08-12 Sankyo Co Pharmaceutical compositions
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3884916A (en) 1971-03-30 1975-05-20 Janssen Pharmaceutica Nv 2,2-Diaryl-4-(4-aryl-4-hydroxy-piperidino)-butyramides
US3714159A (en) 1971-03-30 1973-01-30 Janssen Pharmaceutica Nv 2,2-diaryl-4-(4'-aryl-4'-hydroxy-piper-idino)-butyramides
US4326074A (en) 1972-09-22 1982-04-20 William H. Rorer, Inc. Amidinoureas
US4025652A (en) 1975-03-31 1977-05-24 William H. Rorer, Inc. Amidinoureas
US3937801A (en) 1973-07-10 1976-02-10 American Home Products Corporation Reducing the incidence of gastrointestinal side effects during the treatment of inflammatory conditions with antiinflammatory drugs
US4060635A (en) 1975-03-31 1977-11-29 William H. Rorer, Inc. Amidinoureas for treating diarrhea
US4203920A (en) 1975-03-31 1980-05-20 William H. Rorer, Inc. Amidinoureas
US4072686A (en) 1975-04-16 1978-02-07 G. D. Searle & Co. 1-(3,3,3-Triarylalkyl)-4-phenyl-piperidinealkanols
US4066654A (en) 1975-04-16 1978-01-03 G. D. Searle & Co. 1-triarylalkyl-4-phenyl-4-piperidine carboxylic acids and derivatives
US3996214A (en) 1976-02-23 1976-12-07 G. D. Searle & Co. 5-(1,1-Diphenyl-4-(cyclic amino) but-2-trans-en-1-yl)-2-alkyl-1,3,4-oxadiazoles and intermediates thereto
US4013668A (en) 1976-03-10 1977-03-22 G. D. Searle & Co. 5-(1,1-diphenyl-3-(5- or 6-hydroxy-2-azabicyclo(2.2.2)oct-2-yl)propyl)-2-alkyl-1,3,4-oxadiazoles and related compounds
US4012393A (en) 1976-03-22 1977-03-15 G. D. Searle & Co. 2-[5-(CYCLIC AMINO) ETHYL-10,11-DIHYDRO-5H-dibenzo[a,d]-cyclohepten-5- yl]-5
US4115400A (en) 1976-05-27 1978-09-19 Eli Lilly And Company 1-Azoniabicyclo[3.1.0]hexanes
GB1593191A (en) 1977-03-23 1981-07-15 Reckitt & Colmann Prod Ltd Derivatives of morphine
US4125531A (en) 1977-04-18 1978-11-14 G. D. Searle & Co. 2-Substituted-1-azabicyclo[2.2.2]octanes
US4069223A (en) 1977-05-02 1978-01-17 G. D. Searle & Co. 4-Aminomethyl-1-(3,3,3-triarylpropyl)-4-arylpiperidine and derivatives thereof
US4116963A (en) 1977-05-23 1978-09-26 G.D. Searle & Co. 3,3,3-triarylalkyl-4-phenylalkyl-4-hydroxy piperidines and related compounds
US4194045A (en) 1977-12-27 1980-03-18 G. D. Searle & Co. 1-(3,3-Diaryl-3-oxadiazolalkyl)-4-phenyl-4-piperidinomethanols and related compounds
JPS5535031A (en) 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
US4311833A (en) 1979-03-06 1982-01-19 Daicel Chemical Industries Ltd. Process for preparing ethylcarboxymethylcellulose
US4277605A (en) 1980-03-07 1981-07-07 Bristol-Myers Company Chemical compounds
US4322426A (en) 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4466968A (en) 1980-11-24 1984-08-21 Dermall, Ltd. Method for prophylaxis or treatment of emesis and nausea
US4427676A (en) 1980-12-19 1984-01-24 John Wyeth & Brother Ltd. Thiomorpholine derivatives
US4377568A (en) 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (en) 1981-11-20 1987-05-25 Benzon As Alfred PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL ORAL POLYDEPOT PREPARATION
JPS59500418A (en) 1982-03-16 1984-03-15 ザ　ロツクフエラ−　ユニバ−シテイ How to recover from gastrointestinal dysfunction
US4870084A (en) 1982-03-16 1989-09-26 Pfizer Inc. Bicyclic benzo fused pyran compounds used for nausea treatment and prevention
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
JPS58142090U (en) 1982-03-20 1983-09-24 幸和産業株式会社 Interlocking prize ball feeder for pachinko machines
US4430327A (en) 1982-05-18 1984-02-07 Eli Lilly And Company Method for treating pregnant females for pain and anxiety
US4457907A (en) 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
US4533739A (en) 1982-10-12 1985-08-06 G. D. Searle & Co. 2-[(Aminophenyl and amidophenyl)amino]-1-azacycloalkanes having antidiarrheal activity
US4518433A (en) 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4462839A (en) 1983-06-16 1984-07-31 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4689332A (en) 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4666716A (en) 1984-09-04 1987-05-19 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof
JPS6229515A (en) 1985-07-30 1987-02-07 Shinjiro Tsuji Method for film-coating of hard capsule
JPH0676314B2 (en) 1985-09-30 1994-09-28 花王株式会社 Suppository base and suppository
US4824853A (en) 1985-10-11 1989-04-25 Janssen Pharmaceutica N.V. α,α-diaryl-4-aryl-4-hydroxy-1-piperidinebutanamide, N-oxides and method of treating diarrhea
US4730048A (en) 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4806556A (en) 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
DE3609073C2 (en) 1986-03-18 1995-08-10 Hans J Prof Dr Rer Nat Schmitt Measuring device for non-invasive detection of peripheral drainage and flow disorders in human extremities
US4990521A (en) 1986-07-03 1991-02-05 Janssen Pharmaceutica 4-(aroylamino)piperidine-butanimide derivatives
DE3777658D1 (en) 1986-08-28 1992-04-23 Enzacor Pty Ltd ANIMAL GROWTH PATH.
US5597564A (en) 1986-08-28 1997-01-28 Enzacor Properties Limited Method of administering a microgranular preparation to the intestinal region of animals
US4888346A (en) 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
US4765978A (en) 1986-12-16 1988-08-23 Schering Corporation Novel vaginal suppository
FR2609632B1 (en) 1987-01-21 1991-03-29 Shelly Marc NOVEL THERAPEUTIC APPLICATION OF 17- (CYCLOPROPYLMETHYL) -4,5-EPOXY-3,14-DIHYDROXYMORPHINON-6-ONE AND PHARMACEUTICAL COMPOSITIONS FOR THIS USE
NL8700842A (en) 1987-04-10 1988-11-01 Duphar Int Res
US4891379A (en) 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
US4857833A (en) * 1987-08-27 1989-08-15 Teradyne, Inc. Diagnosis of faults on circuit board
CA1315689C (en) 1987-09-03 1993-04-06 Leon I. Goldberg Quarternary derivatives of noroxymorphone which relieve nausea and emesis
ES2051742T3 (en) 1987-09-10 1994-07-01 Univ Chicago QUARTERLY DERIVATIVES OF NOROXI-MORPHINE THAT MITIGATE NAUSEA AND EMESIS.
US4912114A (en) 1988-03-18 1990-03-27 Sandoz Ltd. Morphinan derivatives
ES2085865T3 (en) 1988-06-30 1996-06-16 Astra Ab DERMORPHINE ANALOGS, THEIR PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC TREATMENT METHODS THAT USE THEM.
EP0352361A1 (en) 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4999342A (en) 1988-08-16 1991-03-12 Ortho Pharmaceutical Corporation Long lasting contraceptive suppository composition and methods of use
US4857533A (en) 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5116868A (en) 1989-05-03 1992-05-26 The Johns Hopkins University Effective ophthalmic irrigation solution
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US4965269A (en) 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5236947A (en) 1990-02-28 1993-08-17 Jouveinal S.A. Propanamines, their pharmacological properties and their application as an antidiarrheal
JPH0813748B2 (en) 1990-04-23 1996-02-14 帝國製薬株式会社 Colon disintegrating polypeptide oral preparation
ATE148632T1 (en) 1990-05-11 1997-02-15 Pfizer SYNERGISTIC THERAPEUTIC COMPOSITIONS AND METHODS
US5366979A (en) * 1990-06-07 1994-11-22 Pharmaco Development Partners Orally active nonaddicting analgesics
JP3160862B2 (en) 1990-11-15 2001-04-25 雪印乳業株式会社 Bone-fortified foods, feeds and pharmaceuticals
JPH04230625A (en) 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd Method for production of finely dispersed tablet composition consisting of microcapsule containing sprayed and dried sodium dichlofenac and having enteric coating
CA2104229C (en) 1991-02-25 1997-04-15 Conan Kornetsky Opiate receptor antagonist modulates movement disorder
JP2916290B2 (en) 1991-03-22 1999-07-05 帝國製薬株式会社 Colon-disintegrating oral preparation containing bioactive polypeptide
US5270328A (en) 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5250542A (en) 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
CA2064373C (en) 1991-03-29 2005-08-23 Buddy Eugene Cantrell Piperidine derivatives
US5220017A (en) 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
ATE158180T1 (en) 1991-06-21 1997-10-15 Univ Cincinnati ORALLY ADMINISTERED THERAPEUTIC PROTEINS AND PRODUCTION METHODS
JPH0550863A (en) 1991-08-19 1993-03-02 Aisin Aw Co Ltd Electric motor device for vehicle
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5614219A (en) 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
US5256154A (en) 1992-01-31 1993-10-26 Sterling Winthrop, Inc. Pre-filled plastic syringes and containers and method of terminal sterilization thereof
JPH05213763A (en) 1992-02-10 1993-08-24 Sanwa Kagaku Kenkyusho Co Ltd Readily absorbable activated calcium preparation
NL9220019A (en) 1992-04-10 1994-04-05 Vnii Med Polimerov PHARMACEUTICAL COMPOSITION.
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
USRE36547E (en) 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5512578A (en) 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
HU225646B1 (en) 1992-10-28 2007-05-29 Genentech Inc Hvegf receptors as vascular endothelial cell growth factor antagonists
DK0603992T4 (en) 1992-12-22 2001-03-05 Univ Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins
DE4303214A1 (en) 1993-02-04 1994-08-11 Wolfgang Marks Treatment of diseases of viral, viroidal or oncogenic origin by steroid saponins or their aglycones
US5585348A (en) 1993-02-10 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5391372A (en) 1993-06-28 1995-02-21 Campbell; Elizabeth Methods of treating colic and founder in horses
ES2146654T3 (en) 1993-07-23 2000-08-16 Toray Industries DERIVATIVE OF MORFINANO AND MEDICAL USE.
GB2281205A (en) 1993-08-24 1995-03-01 Euro Celtique Sa Oral opioid analgesic
SE9303744D0 (en) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
US5434171A (en) 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
DE69503126T2 (en) 1994-05-05 1998-11-12 Beckman Instruments Inc REPETITIVE OLIGONUCLEOTIDE MATRIX
IT1269826B (en) 1994-05-24 1997-04-15 Paolo Minoia USE OF OPTIACEAN ANTAGONISTS AND CALCIUM SALTS FOR THE PREPARATION OF MEDICATIONS FOR THE TREATMENT OF ENDORPHINE-MEDIATED PATHOLOGICAL FORMS
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5614222A (en) 1994-10-25 1997-03-25 Kaplan; Milton R. Stable aqueous drug suspensions and methods for preparation thereof
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
ES2094694B1 (en) 1995-02-01 1997-12-16 Esteve Quimica Sa NEW PHARMACEUTICALLY STABLE FORMULATION OF A COMPOUND OF BENZMIDAZOLE AND ITS PROCESS OF OBTAINING.
US6096763A (en) 1995-02-23 2000-08-01 Merck & Co., Inc. α1a adrenergic receptor antagonists
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
GB9517001D0 (en) 1995-08-18 1995-10-18 Denny William Enediyne compounds
US5804595A (en) 1995-12-05 1998-09-08 Regents Of The University Of Minnesota Kappa opioid receptor agonists
ATE208760T1 (en) 1995-12-21 2001-11-15 Syngenta Participations Ag 3-AMINO-2-MERCAPTOBENZOIC ACID DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
DE69725345T2 (en) 1996-02-15 2004-08-19 Janssen Pharmaceutica N.V. USE OF 5-HT4 ANTAGONISTS TO OVERCOME THE GASTROINTESTINAL DAMAGE CAUSED BY SEROTONIN REINVISION INHIBITORS
WO1997033566A2 (en) 1996-03-12 1997-09-18 Alza Corporation Composition and dosage form comprising opioid antagonist
US6136780A (en) 1996-03-29 2000-10-24 The Penn State Research Foundation Control of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (ζ) receptor
US20040024006A1 (en) 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
DE19651551C2 (en) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioid antagonist-containing galenic formulation
US20010036469A1 (en) 1997-01-13 2001-11-01 Gooberman Lance L. Opiate antagonist implant and process for preparation therefor
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
HU9701081D0 (en) 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
US6525038B1 (en) 1997-06-24 2003-02-25 Werner Kreutz Synergistic compositions for the selective control of tumor tissue
US6353004B1 (en) 1997-07-14 2002-03-05 Adolor Coporation Peripherally acting anti-pruritic opiates
US6096764A (en) 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
US6099853A (en) 1997-09-04 2000-08-08 Protein Express Vaginal suppository vaccine for urogenital infections
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
AU2003204844B2 (en) 1997-11-03 2007-06-07 Arch Development Corporation Use of methylnaltrexone and related compounds
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6777534B1 (en) 1997-12-09 2004-08-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
RU2241458C2 (en) 1997-12-22 2004-12-10 Эро-Селтик, С.А. Combinations of agonist/antagonist for opioid
EP0930334A1 (en) 1998-01-16 1999-07-21 Quest International B.V. Polysaccharide conjugate capable of binding cellulose
GB9802251D0 (en) 1998-02-03 1998-04-01 Ciba Geigy Ag Organic compounds
ES2267255T3 (en) 1998-04-03 2007-03-01 Ajinomoto Co., Inc. ANTITUMOR AGENTS.
US6359111B1 (en) 1998-05-28 2002-03-19 Neorx Corporation Opioid receptor targeting
HN1999000149A (en) 1998-09-09 2000-01-12 Pfizer Prod Inc DERIVATIVES OF 4,4-BIARILPIPERIDINA
US20010010919A1 (en) 1998-10-13 2001-08-02 David K. Grandy Opioid antagonists and methods of their use
US6194382B1 (en) 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
JP4049477B2 (en) 1999-03-23 2008-02-20 大鵬薬品工業株式会社 Side effect reducing agent
US7129265B2 (en) 1999-04-23 2006-10-31 Mason R Preston Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
US6171620B1 (en) 1999-04-27 2001-01-09 Health Research, Inc. Method of enhancing the efficacy of anti-tumor agents
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US20020068712A1 (en) 1999-07-23 2002-06-06 Troy Stevens Use of decreasing levels of functional transient receptor potential gene product
US20030105121A1 (en) 1999-07-27 2003-06-05 Bernard Bihari Method of preventing lipodystrophy syndrome or reversing a pre-existing syndrome in HIV-infected patients being treated with antiretroviral agents
EP1206264A2 (en) 1999-08-25 2002-05-22 Barrett R. Cooper Compositions and methods for treating opiate intolerance
CA2388560A1 (en) 1999-08-31 2001-03-08 Grunenthal Gmbh Sustained-release form of administration containing tramadol saccharinate
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
EP1225897B1 (en) 1999-11-01 2004-09-08 RHODES, John Composition for treatment of constipation and irritable bowel syndrome
ES2251168T3 (en) 1999-11-04 2006-04-16 Institut Gustave Roussy ANTIVIRAL AGENT IN COMBINATION WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER.
US6384044B1 (en) 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
ATE432076T1 (en) 1999-11-29 2009-06-15 Adolor Corp NEW METHODS AND PROCEDURES FOR TREATING AND PREVENTING ILEUS
WO2001037785A2 (en) 1999-11-29 2001-05-31 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
WO2001041705A2 (en) 1999-11-29 2001-06-14 Adolor Corporation Novel methods for the treatment and prevention of dizziness and pruritus
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
US20010046968A1 (en) 2000-03-23 2001-11-29 Zagon Ian S. Opioid growth factor modulates angiogenesis
US6967075B2 (en) 2000-04-07 2005-11-22 Schering Corporation HCV replicase complexes
JP2004515455A (en) 2000-05-05 2004-05-27 ペイン・セラピューティクス・インコーポレイテッド Opioid antagonist compositions and dosage forms
AU7013401A (en) 2000-06-22 2002-01-02 Univ Iowa Res Found Methods for enhancing antibody-induced cell lysis and treating cancer
EP1175905A1 (en) 2000-07-24 2002-01-30 Societe Des Produits Nestle S.A. Nutritional Composition
FI116089B (en) 2000-07-27 2005-09-15 Johan Tore Karlstroem Device and procedures for controls
MXPA03000771A (en) 2000-07-28 2003-06-04 Hoffmann La Roche New pharmaceutical composition.
NZ507152A (en) 2000-09-27 2001-06-29 Hiltive Pty Ltd Wall cladding assembly with cladding having recesses along opposite sides to engage with flanges of support members
AU2002249885A1 (en) 2000-11-17 2002-08-12 Adolor Corporation Delta agonist analgesics
JP4472253B2 (en) 2000-12-04 2010-06-02 プリマゲン ベー．フェー． Examination of internal symbiotic organelles and compounds identifiable thereby
CA2431173A1 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
TW574512B (en) * 2001-03-14 2004-02-01 Koninkl Philips Electronics Nv Electrophoretic display device
MXPA03008623A (en) 2001-03-23 2004-05-21 Shire Biochem Inc Pharmaceutical combinations for the treatment of cancer.
US20040242523A1 (en) 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
WO2002080987A1 (en) 2001-04-09 2002-10-17 Progenics Pharmaceuticals, Inc. Anti-cd19 immunotoxins
WO2002087586A1 (en) 2001-04-26 2002-11-07 Control Delivery Systems, Inc. Sustained release drug delivery system containing codrugs
CA2449175A1 (en) 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
WO2003020296A1 (en) 2001-08-31 2003-03-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College INHIBITION OF ANGIOGENESIS AND DESTRUCTION OF ANGIOGENIC VESSELS WITH EXTRACTS OF NONI JUICE $i(MORINDA CITRIFOLIA)
US7056500B2 (en) 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
US20030144312A1 (en) 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
WO2003037365A1 (en) 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
CA2470519C (en) 2001-12-21 2009-11-17 Merck & Co., Inc. Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
US20050011468A1 (en) 2002-02-04 2005-01-20 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
US20040259898A1 (en) 2002-02-04 2004-12-23 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
AU2003219863C1 (en) * 2002-02-22 2009-03-05 Shire Llc Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US7074825B2 (en) 2002-03-07 2006-07-11 Huanbiao Mo Composition and method for treating cancer
WO2003077867A2 (en) 2002-03-14 2003-09-25 Euro-Celtique, S.A. Naltrexone hydrochloride compositions
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US7355081B2 (en) 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
EP1515754B1 (en) 2002-05-17 2011-05-25 Board Of Regents, The University Of Texas System Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US6986901B2 (en) 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions
US20040010997A1 (en) 2002-07-17 2004-01-22 Oren Close Guides to align masonry walls defining apertures, and methods of use
US7160913B2 (en) 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
US7691374B2 (en) 2002-10-23 2010-04-06 Health Research, Inc. Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody
AU2003296954A1 (en) 2002-12-13 2004-07-09 The Regents Of The University Of California Analgesic combination comprising nalbuphine
WO2004054569A1 (en) 2002-12-16 2004-07-01 Council Of Scientific And Industrial Research Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings
ATE406360T1 (en) 2003-03-07 2008-09-15 Lilly Co Eli ANTAGONISTS OF OPIOID RECEPTORS
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
US20050004155A1 (en) 2003-04-08 2005-01-06 Boyd Thomas A. Use of methylnaltrexone to treat irritable bowel syndrome
CN1767855A (en) 2003-04-08 2006-05-03 普罗热尼奇制药公司 Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
RU2350327C2 (en) 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Compounds causing weight loss
US6992193B2 (en) 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use
PL1644021T3 (en) 2003-06-13 2013-01-31 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
AU2003903387A0 (en) 2003-07-02 2003-07-17 Sirtex Medical Limited Combination therapy for treatment of neoplasia
WO2005041759A2 (en) 2003-10-29 2005-05-12 Allez Physionix Ltd. Method and apparatus for determining an ultrasound fluid flow centerline
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
WO2005087208A2 (en) 2004-03-10 2005-09-22 Trustees Of Tufts College Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
US6946556B1 (en) 2004-05-21 2005-09-20 Acura Pharmaceuticals, Inc. Preparation of opioid analgesics by a one-pot process
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US7725072B2 (en) * 2004-06-30 2010-05-25 Glenayre Electronics, Inc. Provision of messaging services from a video messaging system based on ANI and CLID
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
EP2301963A1 (en) 2004-09-23 2011-03-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
CN101061073A (en) 2004-09-30 2007-10-24 贝克顿·迪金森公司 Method for reducing or eliminating residue in a glass medical container and container made in accordance therewith
US20060205753A1 (en) 2005-01-20 2006-09-14 Israel Robert J Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
MX2007010833A (en) 2005-03-07 2009-02-17 Univ Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration.
AR057035A1 (en) 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057325A1 (en) 2005-05-25 2007-11-28 Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
EP1901742A2 (en) 2005-06-03 2008-03-26 The University of Chicago Modulation of cell barrier dysfunction
US20080194611A1 (en) 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
CA2610951A1 (en) 2005-06-03 2006-12-14 The University Of Chicago Modulation of microbial pathogen-host cell interactions
MX2007015287A (en) 2005-06-09 2008-02-22 Mallinckrodt Inc Method for separation and purification of naltrexone by preparative chromatography.
PE20070207A1 (en) 2005-07-22 2007-03-09 Genentech Inc COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
EP1942903A4 (en) 2005-08-30 2011-01-12 Univ Kingston Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to opioid receptor agonists using an ultralow dose of an alpha-2 receptor antagonist
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20070259939A1 (en) 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
WO2008011596A2 (en) 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
TWI489984B (en) 2006-08-04 2015-07-01 Wyeth Corp Formulations for parenteral delivery of compounds and uses thereof
TW200815451A (en) 2006-08-04 2008-04-01 Wyeth Corp 6-carboxy-normorphinan derivatives, synthesis and uses thereof
TW200817048A (en) 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
CA2670386A1 (en) 2006-11-22 2008-05-29 Progenics Pharmaceuticals, Inc. Processes for synthesizing quaternary 4,5-epoxy-morphinan analogs and isolating their n-stereoisomers
EP2101773A2 (en) 2006-11-22 2009-09-23 Progenics Pharmaceuticals, Inc. (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
AU2007329590A1 (en) 2006-11-22 2008-06-12 Progenics Pharmaceuticals, Inc. N-oxides of 4,5-epoxy-morphinanium analogs
DK2139890T3 (en) 2007-03-29 2014-08-25 Wyeth Llc PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND APPLICATIONS THEREOF
MX351611B (en) 2007-03-29 2017-10-20 Wyeth Llc Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof.
CA2682125C (en) 2007-03-29 2015-06-16 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
WO2004043964A2 (en) * 2002-11-08 2004-05-27 Mallinckrodt Inc. Process for the preparation of quaternary n-alkyl morphinan alkaloid salts

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIANCHETTI A ET AL: "QUATERNARY DERIVATIVES OF NARCOTIC ANTAGONISTS : STEREOCHEMICAL REQUIREMENTS AT THE CHIRAL NITROGEN FOR IN VITRO AND VIVO ACTIVITY", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 33, no. SUPPL 1, 1983, pages 415 - 418, XP000980615, ISSN: 0024-3205 *
DE PONTI F: "METHYLNALTREXONE PROGENICS", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 3, no. 4, April 2002 (2002-04-01), pages 614 - 620, XP009066298, ISSN: 1472-4472 *
FUNKE, CAREL W. ET AL: "A proton and carbon-13 nuclear magnetic resonance study of three quaternary salts of naloxone and oxymorphone", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 2: PHYSICAL ORGANIC CHEMISTRY (1972-1999) , (5), 735-8 CODEN: JCPKBH; ISSN: 0300-9580, 1986, XP009072982 *
IORIO, MARIA A. ET AL: "Narcotic agonist/antagonist properties of quaternary diastereoisomers derived from oxymorphone and naloxone", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , 19(4), 301-3 CODEN: EJMCA5; ISSN: 0223-5234, 1984, XP009072981 *
KOBYLECKI R J: "N-METHYLNALORPHINE: DEFINITION OF N-ALLYL CONFORMATION FOR ANTAGONISM AT THE OPIATE RECEPTOR", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 25, no. 11, 1982, pages 1278 - 1280, XP000978843, ISSN: 0022-2623 *
YUAN CHUN-SU: "Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects./TRIALS SO FAR SHOW THAT THIS PERIPHERAL OPIOID RECEPTOR ANTAGONIST CAN PREVENT OPIOID-INDUCED CONSTIPATION WITHOUT DIMINISHING PAIN PALLIATION", JOURNAL OF SUPPORTIVE ONCOLOGY, BIOLINK COMMUNICATIONS,, US, vol. 2, no. 2, March 2004 (2004-03-01), pages 111 - 117, XP002390438, ISSN: 1544-6794 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9526723B2 (en) 2008-03-21 2016-12-27 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US9518062B2 (en) 2009-07-16 2016-12-13 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
US9527858B2 (en) 2009-07-16 2016-12-27 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers

Also Published As

Publication number Publication date
JP5213704B2 (en) 2013-06-19
SI1913001T1 (en) 2013-11-29
US20170143700A1 (en) 2017-05-25
AU2006249911C1 (en) 2012-12-20
HK1244267A1 (en) 2018-08-03
JP2013075905A (en) 2013-04-25
JP2015129190A (en) 2015-07-16
DK1913001T3 (en) 2013-10-21
US20150290187A1 (en) 2015-10-15
AR057035A1 (en) 2007-11-14
CN102721756A (en) 2012-10-10
MY151036A (en) 2014-03-31
WO2006127899A2 (en) 2006-11-30
US7674904B2 (en) 2010-03-09
MX2007014880A (en) 2008-02-15
CN101208344A (en) 2008-06-25
BRPI0611162A2 (en) 2010-08-17
HN2006019068A (en) 2011-03-02
EP3219717A1 (en) 2017-09-20
US20100311781A1 (en) 2010-12-09
EP2450359A3 (en) 2012-08-22
US20130323286A1 (en) 2013-12-05
JP5769693B2 (en) 2015-08-26
US9597327B2 (en) 2017-03-21
AU2006249911A1 (en) 2006-11-30
CA2609662A1 (en) 2006-11-30
TWI383984B (en) 2013-02-01
PL1913001T3 (en) 2013-12-31
EP2450359A2 (en) 2012-05-09
US20150057303A1 (en) 2015-02-26
ES2429160T3 (en) 2013-11-13
CN101208344B (en) 2012-10-24
CA2609662C (en) 2016-08-16
EP1913001B1 (en) 2013-09-04
JP2008542287A (en) 2008-11-27
PT1913001E (en) 2013-10-08
EP1913001A2 (en) 2008-04-23
AU2006249911B2 (en) 2012-05-17
JP2017137346A (en) 2017-08-10
US8343992B2 (en) 2013-01-01
GT200600226A (en) 2007-01-12
TW200716647A (en) 2007-05-01
US20070099946A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
WO2006127899A3 (en) (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
WO2006127898A3 (en) (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
WO2005112938A3 (en) Disalt inhibitors of il-12 production
WO2007127841A3 (en) Compositions and methods of preparation thereof
WO2008017029A3 (en) Drug carriers, their synthesis, and methods of use thereof
WO2005108358A3 (en) Pyrrolidine derivatives useful as bace inhibitors
WO2006092213A8 (en) Pyrazolylcarboxanilides
WO2006023627A8 (en) Rapamycin polymorph ii and uses thereof
WO2008005877A3 (en) Inhibitors of c-kit and uses thereof
WO2007022459A3 (en) Processes and intermediates
WO2008151170A3 (en) Process for the synthesis of ramelteon and its intermediates
WO2006075095A3 (en) Use of purine derivatives as hsp90 protein inhibitors and for treatment of cancer
WO2008013990A3 (en) Processes for the synthesis of o-desmethylvenlafaxine
WO2007062370A3 (en) Calcilytic compounds
IL188919A (en) Process for the preparation of mandipropamid and derivatives thereof and intermediates therefor
WO2007067784A3 (en) Liposomal compositions
WO2007047671A3 (en) Tetrahydroquinolines, synthesis thereof, and intermediates thereto
WO2004106322A3 (en) Polymorphs of aripiprazole
WO2009137714A3 (en) Forms of lapatinib ditosylate and processes for preparation thereof
WO2007016029A3 (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto
WO2007098273A3 (en) Novel crystalline forms of armodafinil and preparation thereof
WO2007061878A3 (en) 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
WO2007016609A3 (en) Method for the synthesis of quinoliνe derivatives
WO2009155403A3 (en) Processes for the preparation of varenicline and intermediates thereof
WO2009111785A3 (en) Treatment of sepsis with 5-ethyl-1-phenyl-2(1h)-pyridone and novel methods for synthesis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680022957.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2609662

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/014880

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2008513707

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 4550/KOLNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006771163

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006249911

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: 2006249911

Country of ref document: AU

Date of ref document: 20060525

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0611162

Country of ref document: BR

Kind code of ref document: A2